Argentum settles Restasis dispute with Allergan

Generic drug company Argentum Pharmaceuticals LLC said it reached a settlement and license agreement with Allergan, Inc. related to Argentum’s generic version of Allergan’s dry eye drug Restasis.

“The agreement generally provides that Argentum may commence marketing its generic equivalent product sometime prior to the expiration of the patents covering Restasis,” said Argentum.

“The specific date on which Argentum may launch its generic product and other details concerning the settlement have not been disclosed.”